The Nature of Progression in Parkinson's Disease: An Application of Non-Linear, Multivariate, Longitudinal Random Effects Modelling

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Kuramoto, Lisa ^a   Cragg, Jacquelyn ^b   Nandhagopal, Ramachandiran ^b   Mak, Edwin ^b   Sossi, Vesna ^b   de la Fuente Fernández, Raul ^b   Stoessl, A Jon ^b   Schulzer, Michael ^a,b  

^a VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASYMPTOMATIC DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE DURATION; HUMAN; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NONLINEAR SYSTEM; ONSET AGE; PARKINSON DISEASE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; RANDOMIZATION; STATISTICAL MODEL;

AGE FACTORS; AGE OF ONSET; ALGORITHMS; ASYMPTOMATIC DISEASES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; HUMANS; LONGITUDINAL STUDIES; MODELS, STATISTICAL; PARKINSON DISEASE; PUTAMEN; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 84885755318     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076595     Document Type: Article

References (30)

1. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, et al. (2007) How common are the "common" neurologic disorders? Neurology 68: 326-337.
2. Scheife RT, Schumock GT, Burstein A, Gottwald MD, Luer MS, (2000) Impact of parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes. American Journal of Health-System Pharmacy 57: 953-962.
3. Rubenstein LM, Chrischilles EA, Voelker MD, (1997) The impact of parkinson's disease on health status, health expenditures, and productivity. estimates from the national medical expenditure survey. Pharmacoeconomics 12: 486-498.
4. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, et al. (2004) Levodopa and the progression of parkinson's disease. New England Journal of Medicine 351: 2498-2508.
5. Au WL, Adams JR, Troiano AR, Stoessl AJ, (2005) Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. Molecular Brain Research 134: 24-33.
6. Brooks DJ, Frey KA, Marek KL, Oakes D, Paty D, et al. (2003) Assessment of neuroimaging techniques as biomarkers of the progression of parkinson's disease. Experimental Neurology 184: S68-S79.
7. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, et al. (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in parkinson's disease. Annals of Neurology 47: 493-503.
8. Adams JR, van Netten H, Schulzer M, Mak E, Mckenzie J, et al. (2005) Pet in lrrk2 mutations: comparison to sporadic parkinson's disease and evidence for presymptomatic compensation. Brain 128: 2777-2785.
9. Nandhagopal R, McKeown M, Stoessl AJ, (2008) Functional imaging in parkinson disease. Neurology 70: 1478-1488.
10. Marshall G, De la cruz Mesia R, Baron AE, Rutledge JH, Zerbe GO, (2006) Non-linear random effects model for multivariate responses with missing data. Statistics in Medicine 25: 2817-2830.
11. Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S, et al. (2005) Nonlinear progression of parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa f 18 activity. Archives of Neurology 62: 378-382.
12. Huang C, Tang C, Feigin A, Lesser M, Ma Y, et al. (2007) Changes in network activity with the progression of parkinson's disease. Brain 130: 1834-1846.
13. Brück A, Aalto S, Nurmi E, Vahlberg T, Bergman J, et al. (2006) Striatal subregional 6-[18f]fluorol-dopa uptake in early parkinson's disease: a tow-year follow-up study. Movement Disorders 21: 958-963.
14. Lee CS, Schulzer M, de la Fuente-Fernandez R, Mak E, Kuramoto L, et al. (2004) Lack of regional selectivity during the progression of parkinson disease: implications for pathogenesis. Archives of Neurology 61: 1920-1925.
15. Schwarz J, Storch A, Koch W, Pogarell O, Radau PE, et al. (2004) Loss of dopamine transporter binding in parkinson's disease follows a single exponential rather than linear decline. Journal of Nuclear Medicine 10: 1694-1697.
16. Morrish PK, Sawle GV, Brooks DJ, (1996) An [18f]dopa-pet and clinical study of the rate of progression in parkinson's disease. Brain 119: 585-591.
17. Morrish PK, Rakshi JS, Bailey DL, Sawle Gv, Brooks DJ, (1998) Measuring the rate of progression and estimating the preclinical period of parkinson's disease with [18f]dopa pet. Journal of Neurology, Neurosurgery, and Psychiatry with Practical Neurology 64: 314-319.
18. Ratkowsky DA (1990) Handbook of nonlinear regression models, 1st edition. Marcel Dekker.
19. Davidian M, Giltinan DM (1995) Nonlinear models for repeated measurement data, 1st edition. Chapman & Hall.
20. Laird NM, Ware JH, (1982) Random-effects models for longitudinal data. Biometrics 38: 963-974.
21. Lindstrom MJ, Bates DM, (1990) Nonlinear mixed effects models for repeated measures data. Biometrics 46: 673-687.
22. Spinks TJ, Jones T, Bailey DL, Townsend DW, Grootoonk S, et al. (1992) Physical performance of a positron tomograph for brain imaging with retractable septa. Physics in Medicine and Biology 37: 1637-1655.
23. Armitage P, Colton T (1998) Encyclopedia of Biostatistics, chapter Delta Method. John Wiley. 1125-1127.
24. Fleiss JL, Levin B, Paik MC (2003) Statistical Methods for Rates and Proportions, 3rd edition. Wiley.
25. Draper NR, Smith H (1998) Applied Regression Analysis, 3rd edition. Wiley.
26. Brent R (1973) Algorithms for Minimization without Derivatives, 1st edition. Prentice-Hall.
27. R Development Core Team (2006) R: A Language and Environment for Statistical Computing. The R Project for Statistical Computing website. Available: http://www.R-project.org. Accessed 2013 Sep 16.
28. Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, et al. (2009) Longitudinal progression of sporadic parkinsons disease: a multitracer pet study. Brain 132: 2970-2979.
29. de la Fuente-Fernandez R, Schulzer M, Kuramoto L, Cragg J, Nandhagopal R, et al. (2011) Agespecific patterns of neurodegeneration in parkinson's disease. Annals of Neurology 69: 803-810.
30. Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, et al. (2011) Longitudinal evolution of compensatory changes in striatal dopamine processing in parkinson's disease. Brain 134: 3290-3298.